Market: NASD |
Currency: USD
Address: 1020 Stony Hill Road
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Show more
📈 OptiNose, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$9.00
-
Upside/Downside from Analyst Target:
-6.25%
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
0-10%
-
Revenue Growth Range (1Y):
10-25%
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2024 |
- |
$0.066667 |
- |
2024-12-31 |
- |
Stock split |
|
Total Amount for 2024: $0.066667 |
📅 Earnings & EPS History for OptiNose, Inc.
| Date | Reported EPS |
|---|
| 2025-05-14 | -1.92 |
| 2025-03-26 | -0.03 |
| 2024-11-12 | - |
| 2024-08-08 | -0.75 |
| 2024-05-14 | -1.8 |
| 2024-03-07 | -1.35 |
| 2023-11-09 | -1.2 |
| 2023-08-10 | 0.3 |
| 2023-05-11 | -2.55 |
| 2023-03-07 | -2.55 |
| 2022-11-10 | -2.7 |
| 2022-08-11 | -3.45 |
| 2022-05-12 | -4.65 |
| 2022-03-08 | -3.45 |
| 2021-11-15 | -4.8 |
| 2021-08-11 | -6.6 |
| 2021-05-05 | -7.35 |
| 2021-03-03 | -6.9 |
| 2020-11-05 | -6.45 |
| 2020-08-04 | -8.4 |
| 2020-05-07 | -9.45 |
| 2020-03-05 | -8.7 |
| 2019-11-12 | -10.35 |
| 2019-08-12 | -9.9 |
| 2019-05-09 | -10.5 |
📰 Related News & Research
No related articles found for "optinose inc".
